Observational Prospective Study of Survival, Treatment Patterns, Disease and Economic Outcomes in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Progression During or After a First-line Docetaxel-based Regimen.

Trial Profile

Observational Prospective Study of Survival, Treatment Patterns, Disease and Economic Outcomes in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Progression During or After a First-line Docetaxel-based Regimen.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs Antineoplastics; Docetaxel; Taxanes
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms PORTREAT
  • Sponsors Sanofi
  • Most Recent Events

    • 29 Aug 2012 New source identified and integrated (German Clinical Trials Register: DRKS00004060).
    • 11 Feb 2011 Actual end date (1 Oct 2010) added as reported by ClinicalTrials.gov.
    • 11 Feb 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top